E. Ohman J or Asset Management AB Purchases Shares of 140,617 Pfizer Inc. $PFE

E. Ohman J or Asset Management AB purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 140,617 shares of the biopharmaceutical company’s stock, valued at approximately $3,501,000.

A number of other hedge funds also recently modified their holdings of the business. Fiduciary Alliance LLC raised its position in shares of Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after acquiring an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Pfizer in the third quarter worth approximately $3,019,000. Money Concepts Capital Corp boosted its holdings in Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after acquiring an additional 57,188 shares during the last quarter. Vista Investment Partners LLC increased its position in Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after purchasing an additional 48,900 shares during the period. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in Pfizer during the 3rd quarter valued at approximately $16,613,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. HSBC lifted their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Royal Bank Of Canada assumed coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.14.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 topline shows robust efficacy (~73% in pre-specified analyses), signaling clear commercial potential if regulators accept the data and approve the shot. BusinessWire: Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
• Positive Sentiment: Pfizer’s defensive income profile (high dividend yield cited in market coverage) and recent YTD recovery are attracting dividend‑focused investors, providing demand support amid market volatility. MarketBeat: 5 High-Yield Stocks to Shield Your Portfolio From the Storm
• Positive Sentiment: Technical/market narrative: coverage notes Pfizer is showing signs of outperformance versus prior years, which can attract momentum and rotation flows into the name. Fool: Pfizer Stock Is Doing Something It Hasn’t Done Since 2022
• Neutral Sentiment: Pfizer says it will pursue regulatory submissions despite the trial missing its formal primary endpoint — this keeps an approval path alive but raises review uncertainty and timing questions. CNBC: Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
• Negative Sentiment: The trial failed to meet its primary endpoint due to a low number of infection events, making the results statistically inconclusive and injecting regulatory and commercial risk; partner Valneva’s stock plunged on the news, reflecting investor concern about approval odds and program economics. WSJ: Pfizer’s Lyme Vaccine Shows Strong Efficacy but Misses Mark in Study

Pfizer Trading Down 0.7%

NYSE:PFE opened at $26.77 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a market cap of $152.23 billion, a PE ratio of 19.68 and a beta of 0.47. The firm has a 50-day moving average of $26.71 and a 200-day moving average of $25.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.